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of M peaks abxe 5 &ml mse fmn 3.7 2 0.8 to 6.8 t 3.3 Twenty four hour secretory profiles of growth hormone were measured in 3 children with idiopathic short stature before and 48 hours after 6 months of treatment with rhGH. The study was undertaken to assess the possibility that exogenous GH might impair endogenous secretion. The children were all prepubertal(mean age 10.5yr2.8). with GH levels greater than 10 nglml on provocacl\e testing. Growth velocity during therapy increased from a mean of 3.8t1.5 to 7.0+1.5cm/yr. (p<0.001). The repeat studies werecarria out under identical conditions in the sleep laboratory. Totalsleep time verified by sleep polysomnography and EEG recordings was identical in both studies (mean 503 vs 505 minutes). Comparison of pre and post treatment GH secretory profiles showed no attenuatior of endogenous GH levels. Between pulses GH concentration was undectable in the pre and post rhGH treatment study.
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DOSE-RESPONSE STUDIES WITH BIOSYNTHETIC HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT PATIENTS.
Increasing doses of biosynthetic human growth hormone (8-hGH) were given subcutaneously to 7 GH deficient subjects for three 14 days periods (2. 4 and 6 IU/day at 20.00 h) followed by 14 days without GH therapy. At the end of each period they were hospitalized for blood sampl ing. A dose-dependent increase in serum GH and somatomedin-C (Sm-C) levels occurred. However. the time course of the serum Sm-C patterns showed a significant fall in the evening during absence of therapy. a significant increase following in:!lections of 2 IU of B-hGH, and constant levels within normal range during treatment with 4 and 6 IU. Plasma glucose was within normal range, with lower fasting levels (at 04.00 h) when no GH was given. Breakfast induced a plasma glucose rise when GH was administered, but no rise without GH, and a dosedependent increase in the post-prandial insulin response. GH therapy increased serum levels of free fatty acids (p < 0.05) and 3-OH-butyrate but had no significant impact on serum triglyceride and cholesterol. We conclude that serum Sm-C levels show consistent GH dose-de endence, and that a GH replacement dose of 2 IUIday (1.5 1~1mflday) is insufficient to maintain normal. diurnal levels. Furthermore, a GH independent diurnal variation in these patients is suggested, and finally it is demonstrated that this authentic GH preparation possesses diabetogenic and lipolytic actions. 
TREATMENT OF SHORT NORMAL PREPUBERTAL CHILDREN WITH GROWTH HORMONE.
The growth reponse to growth hormone (GH) was studied in 9 short normal prepubertal children (6 boys, 3 girls) with a low height velocity. Their average age was 8.2yr (range 4.7-12.1), height standard deviation score (SDS) for chronological age (CA) was -2.6 (-2.0 to -3.7).
All had normal maximum plasma GH responses above lOng/mL to stimulation with clonidine and/or insulin induced hypoglycemia. Assessment of overnight GH secretion by measurement of GH in 20min intervals for 12h yielded low peak levels of 8.7+3.O(SD)ng/rnL and low mean pool values of 1.9+1 .O. With informed consent. treatment uith somatrem (Protropin) O.ll+O.Olmg/kg three times weekly s.c. was then begun and continued for one year. No major side effects were noted. After 6 months of GH therapy, height velocity SDS for CA increased significantly (p<0.001) from a pretreatment mean of -1 .I (-0.6 to -3.0) to +3.4 (-1.0 to +5.7), representing a change from 4.7cm/yr (3.5-6.0) to 9.3 (5.7-12.5).
Height velocity during GH treatment (SDS for CA and cm/yr) inversely correlated with endogenous nocturnal peak GH concentration (r=-0.76, and r=-0.78; both p<0.05). We conclude that some short normal children with low height velocity and low endogenous GH secretion may profit from GH therapy. A major goal should be the proper identification of these patients and careful long-term follow-up to final height. Supported by Genentech, Inc., South san Francisco, California. 
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THE ABSORPTION KINETICS OF SUBCUTANEOUSLY AOMINISTE-RED GROWTH HORMONE: INFLUENCE OF INJECTION VOLUME.
Daily subcutaneous (sc) injections (inj) seems now to be the recommended mode of GH administration. A substantial sc degradation of exogenous GH has previously been reported. The aim of the present study was to evaluate the influence of inj volume on the sc absorption rate and bioavailability of GH. Fourteen healthy adults with a median age of 27.5 years 'and a normal body mass index participated. In a randomized design they all received 3 sc inj of 6 IU biosynthetic human GH (~orditropin~) dissolved in either 0.5. 1 . 0 or 2 ml respectively. At least one week elapsed between each inj, which was given in the morning (8.00h) after which moderate physical activity was allowed.
Blood was sampled hourly for 7 (n-14) to 12 (n=B) hours. The initial absorption rate (2 hour values) tended to be faster with the 2 ml inj volume (P=6.5%).
The 2 ml inj volume also yielded the highest mean peak GH values: 23.7 ng/ml (2 ml), 14.7 ng/ml (1 ml) and 16.9 ng/ml (0.5 ml) (P<0.02). as well as the largest area under the curves (8-15 hours): 89.6 ngxhourlml (2 ml). 
30 patients with T S , aged 4.6-12.6 years were randomly allocated to receive oral ethinyl oestradiol (EE2) (0.5-2.Ouglday) or oxandrolone [OX) (0.625-1.25mglday). Groups were matched for age, karyotype, pre-treatment height SDS for TS and height velocity SDS for TS ( H V SDS) (Ranke) .
HV SDS results (SD) after 0.5-1.0 yrs were as follows:
Pre-Treatment Treatment Response to EE2 was slightly less consistent than to OX (p < 0.051, with 2 non-responders.
Both treatments were well tolerated. Cliteromegaly was noted in 2 on O X ; 3 on EE2 had early breast development.
24 hr growth hormone (GH) profiles were performed in 10 of each group before and during treatment. T h e sum of G H pulse amplitudes (SPA) was calculated using a computer algorithm. (PULSAR).
G H SPA was not changed by either 1 could speculate that a rapid sc absorption diminishes the local degradation of GH and thus increases its bioavailability.
treatment.
Used in appropriate dosage, both agents arc safe, simple and effective agents in Turner syndrome. Neither appears to work via increased G H secretion.
